TAKEDA Pharmaceutical Company Ltd. and M2Gen plan to collaborate with ORIEN to generate broad genomic data from cancer patients. Under the agreement, Takeda will help build M2Gen’s Oncology Research Information Exchange Network Avatar Research Program based on the Total Cancer Care Protocol, a prospective observational study enrolling patients with various cancers, and access information generated...
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
